Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIM-3 Expression in Pediatric Crohn's Disease with Infliximab
NCT01661257Phase 3Completed
- Sponsor
- Samsung Medical Center
- Start
- Oct 2009
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of infliximab in Crohn's disease, sponsored by Samsung Medical Center. Primary endpoint: Expression of TIM-3 and Correlation With Disease Activity at 1 year. Started Oct 2009; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01661257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661257.